Applied DNA Sciences Inc (APDN)

[mrbigglessworth]

Got a response from Debbie Bailey about the drop in stock price and what the company is doing to mitigate or reverse that course

"Thank you for your email.

To begin, the share price is discouraging to us as well as we do not believe that it properly values the business we have today, nor the revenue opportunities we are pursuing that should serve as catalysts for revenue growth tomorrow. We cannot control the share price; what we can control is the execution of our growth strategy, and we are doing just that.

As a long-time shareholder, you are aware that our revenue in recent quarters reflects continued adoption by the cotton, synthetic fiber and consumer asset marking markets. You are also aware that our efforts are focused on deepening our penetration of these established markets and establishing a presence in adjacent markets (industrial materials, pharma/diagnostics/personal care, among others) to generate additional revenue opportunities for our technology platform.

While I cannot answer if we are expecting some very big contracts as that would be selective disclosure, what I can tell you is that we are seeing continued development of commercial activity and a high number of pre-commercial opportunities, both of which we believe lay the groundwork for greater commercial-scale adoption of our technology platform. Specifically, in the second quarter, we saw nine new feasibility studies initiated and five commercial opportunities initiated or expanded. This tells us that our value proposition is being accepted. I refer you to our recent earnings conference call on which our CEO gave more details on this. To summarize, we are seeing that the marketplace is becoming increasingly aware of our technology platform.

Our challenge continues to be the uncertainty around the timing of these conversions. The question, we believe, is not “if”, but “when”, and in the meantime, the number of pre-commercial opportunities is growing. The shelf registration we filed on Monday gives us the financial flexibility to efficiently access the capital markets in support of our growth objectives, including executing on our pipeline of pre-commercial activities.

I hope this gives you more insight into what is happening behind the scenes and a better understanding of why we filed our shelf registration.

Best regards,

Debbie Bailey"